Prostate cancer is the most commonly diagnosed non-cutaneous malignancy in men and the second leading cause of cancer death. Current diagnostic tools include the prostate-specific antigen (PSA) test, digital rectal examination (DRE), and transrectal ultrasound-guided biopsy (TRUS). However, major screening trials have shown these tests increase detection without clearly improving mortality.
PSA testing is limited by poor sensitivity and specificity, meaning it misses some cancers and raises concern about others that may never cause harm. This has fueled a search for better, minimally invasive biomarkers that can more accurately identify true disease.
MicroRNAs (miRNAs) are tiny non-coding RNA molecules (18-25 nucleotides in length) that regulate the expression of up to 60% of human genes. They can act as oncogenes (promoting cancer growth) or tumor suppressors (blocking it), and their abnormal expression patterns are linked to the development and progression of many cancers including prostate cancer.
A critical advantage of miRNAs as biomarkers is their remarkable stability. They resist breakdown by enzymes (ribonucleases), survive variations in pH and temperature, and remain detectable in blood samples. This stability makes them ideal candidates for blood-based cancer testing.
The study enrolled 102 men from a Rapid Access Prostate Assessment Clinic (RAPAC) at Galway University Hospital - a tertiary referral center. Men were referred if they had an elevated PSA, abnormal DRE, or family history of prostate cancer. This represents a genuinely high-risk population, important for evaluating real-world diagnostic performance.
Following biopsy, 75 patients were confirmed to have prostate cancer and 27 had benign findings. Blood samples were collected before biopsy in EDTA tubes to preserve RNA integrity. Whole blood was chosen over serum or plasma because it yields higher miRNA concentrations. Samples were collected between September 2009 and March 2011.
A panel of 12 candidate miRNAs was selected based on prior evidence of dysregulation in prostate cancer tissue and circulation. These included let-7a, miR-21, miR-34a, miR-125b, miR-141, miR-143, miR-145, miR-155, miR-221, miR-375, miR-16, and miR-425. Selection drew from existing research at multiple institutions.
RNA was extracted and converted to complementary DNA using stem-loop primers, then quantified by real-time quantitative PCR (RQ-PCR). Expression levels were calculated using the delta-delta Ct method (delta-delta Ct), normalized against two stable endogenous controls: miR-16 and miR-425. All samples were run in triplicate for reliability.
Of the 12 miRNAs tested, four showed statistically significant differences between cancer and benign groups. Let-7a (a tumor suppressor) was significantly downregulated in prostate cancer patients (p = 0.005). Three oncogenic miRNAs - miR-141, miR-145, and miR-155 - were significantly upregulated in cancer patients (p = 0.014, 0.01, and 0.01 respectively).
The oncomir miR-141 achieved an area under the curve (AUC) of 0.655 with 94% sensitivity and a positive predictive value (PPV) of 73% for distinguishing cancer from benign disease. Let-7a achieved an AUC of 0.678 with 93% sensitivity and a PPV of 70%. Individually, each miRNA showed moderate discriminatory ability.
A fifth miRNA, miR-375, showed a strong trend toward significance (p = 0.075), with upregulation in cancer patients. While not reaching the threshold for statistical significance after Bonferroni correction, its trend is biologically consistent with its known role in cancer progression.
Patient demographics were well matched between the two groups. The cancer group had a median age of 64 years and median PSA of 7.4 micrograms per liter; the benign group had a median age of 65 years and median PSA of 7.45. The similar PSA levels between groups highlight why PSA alone is inadequate for distinguishing cancer from benign disease in this population.
When the four significant miRNAs (let-7a, miR-141, miR-145, and miR-155) were analyzed together using binary logistic regression, their combined diagnostic power exceeded that of any single miRNA. The panel AUC reached 0.783, with sensitivity of 97% and a positive predictive value of 80%.
A high sensitivity of 97% means very few prostate cancers would be missed by this panel - a critical requirement for a screening tool. The positive predictive value of 80% indicates that most positive test results correspond to true cancer, reducing unnecessary biopsies compared to PSA alone.
For risk stratification, let-7a expression decreased progressively from benign to low-risk to intermediate-risk prostate cancer according to the D'Amico risk stratification system (p = 0.04). miR-141 showed significant upregulation with increasing risk category (p = 0.023), suggesting miRNAs may help distinguish not just the presence of cancer but its aggressiveness.
In 20 men who underwent radical retropubic prostatectomy (surgical removal of the prostate), blood was collected before surgery and at a mean of 10 days post-operatively. This analysis tested whether miRNA levels would normalize once the cancer source was removed.
miR-141 levels dropped significantly after surgery, returning to levels similar to those seen in men with benign biopsies. This normalization supports the idea that elevated circulating miR-141 is directly related to the tumor and could serve as a marker of treatment response.
The other three miRNAs (let-7a, miR-145, miR-155) did not return to benign baseline levels within the 10-day post-operative window. This may reflect that these markers are influenced by additional biological processes beyond the tumor itself, or that a longer recovery period is needed for their levels to normalize.
This study represents the first reported downregulation of let-7a in the circulation of prostate cancer patients, consistent with its known role as a tumor suppressor in prostate tissue. The findings also confirm the utility of whole blood (versus serum or plasma) for miRNA analysis, as it provides higher RNA yields and more reliable miRNA detection.
The post-surgical normalization of miR-141 builds on prior evidence from breast cancer and colorectal cancer surgery, where oncogenic miRNA levels have been shown to fall after tumor removal. It raises the possibility that circulating miRNA monitoring could track disease recurrence after treatment.
A practical implication of a 97% sensitive miRNA panel would be its potential to reduce the number of unnecessary TRUS biopsies. Biopsies are invasive, carry infection risk, and cause significant patient anxiety. A blood-based test with high sensitivity could serve as a gatekeeper, directing biopsies only to those most likely to have cancer.
The authors acknowledge a key limitation: men in the benign biopsy group with persistently elevated PSA may harbor undiagnosed cancer that was missed by the initial 12-core biopsy. This could mean some apparent false positives from the miRNA panel are actually true positives, making the panel's real-world performance even better than reported.
The ability of a four-miRNA blood test to detect prostate cancer with 97% sensitivity and an AUC of 0.783 positions it as a potentially superior alternative or complement to PSA-based screening. Unlike PSA, which is elevated in benign prostatic hyperplasia and prostatitis, the miRNA panel reflects cancer-specific molecular dysregulation.
The correlation between miRNA expression and D'Amico risk stratification suggests this panel could help guide decisions about active surveillance versus immediate treatment. Men with low-risk cancer often benefit from watchful waiting; a molecular signature predicting aggressiveness would support more tailored clinical decision-making.
If validated in larger populations, miRNA-based tests could also serve as prognostic markers and treatment response monitors - tracking whether therapies such as chemotherapy or radiation are effectively reducing tumor burden, as demonstrated by the post-prostatectomy drop in miR-141 levels.
This study identified a panel of four circulating miRNAs - let-7a, miR-141, miR-145, and miR-155 - with diagnostic potential that exceeds PSA and DRE for detecting prostate cancer in a high-risk clinical population. Three miRNAs were upregulated and one downregulated in association with confirmed prostate cancer.
Importantly, the expression levels of two miRNAs tracked with disease stage as assessed by D'Amico risk stratification, suggesting these molecules may reflect not just the presence but the severity of disease. This dual utility - diagnosis and staging - strengthens the case for further clinical development.
The stability, detectability, and cancer-associated dysregulation of miRNAs in blood make them highly promising non-invasive biomarkers. The authors call for larger prospective validation studies to confirm these findings before clinical translation, but the foundation laid here is a significant step toward better, less invasive prostate cancer detection.